$NERV
Minerva Neurosciences Inc

2017 Q1 Form 10-K Financial Statement

#000156459017004048 Filed on March 13, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 2015 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.870M $9.750M $1.930M
YoY Change 20.59% 28.63% -56.92%
% of Gross Profit
Research & Development $7.610M $20.44M $6.260M
YoY Change 41.71% 10.29% 110.77%
% of Gross Profit
Depreciation & Amortization $3.302K $16.53K $10.00K
YoY Change -23.56% -4.32%
% of Gross Profit
Operating Expenses $10.49M $30.19M $8.190M
YoY Change 35.18% 15.63% 9.93%
Operating Profit -$10.49M -$30.19M -$8.194M
YoY Change 35.17% 15.63% 10.05%
Interest Expense -$201.5K -$1.030M -$250.0K
YoY Change -25.47% -2.22%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$10.64M -$31.05M -$8.440M
YoY Change 33.0% 14.64% 13.44%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$10.64M -$31.05M -$8.439M
YoY Change 32.99% 14.64% 13.4%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$300.8K -$985.4K -$341.3K
COMMON SHARES
Basic Shares Outstanding 35.29M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $85.40M $83.00M $32.20M
YoY Change 91.48% 157.76% 74.05%
Cash & Equivalents $68.89M $83.00M $14.28M
Short-Term Investments $16.50M $0.00 $17.90M
Other Short-Term Assets $900.0K $900.0K $1.300M
YoY Change 28.57% -30.77% 62.5%
Inventory
Prepaid Expenses $1.196M
Receivables
Other Receivables
Total Short-Term Assets $86.20M $83.90M $33.48M
YoY Change 90.29% 150.45% 73.14%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00 $26.17K
YoY Change -39.76%
Goodwill $14.87M
YoY Change 0.0%
Intangibles $34.20M
YoY Change 0.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $49.10M $49.00M $49.10M
YoY Change -0.06% -0.2% -0.04%
TOTAL ASSETS
Total Short-Term Assets $86.20M $83.90M $33.48M
Total Long-Term Assets $49.10M $49.00M $49.10M
Total Assets $135.3M $132.9M $82.58M
YoY Change 43.28% 60.9% 20.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.300M $1.500M $1.361M
YoY Change 175.0% 7.14% 111.99%
Accrued Expenses $4.800M $3.400M $2.500M
YoY Change 54.84% 36.0% -13.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.000M $4.900M $1.400M
YoY Change 92.31% 250.0%
Total Short-Term Liabilities $13.00M $9.700M $5.320M
YoY Change 86.53% 83.02% 51.59%
LONG-TERM LIABILITIES
Long-Term Debt $2.600M $3.800M $8.500M
YoY Change -64.86% -55.29%
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $2.600M $3.800M $8.500M
YoY Change -64.86% -55.29% 110375.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.00M $9.700M $5.320M
Total Long-Term Liabilities $2.600M $3.800M $8.500M
Total Liabilities $29.00M $27.00M $27.26M
YoY Change 4.32% -1.1% 60.8%
SHAREHOLDERS EQUITY
Retained Earnings -$101.8M
YoY Change 36.24%
Common Stock $157.1M
YoY Change 24.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $106.3M $106.0M $55.32M
YoY Change
Total Liabilities & Shareholders Equity $135.3M $132.9M $82.58M
YoY Change 43.33% 60.9% 20.64%

Cashflow Statement

Concept 2017 Q1 2016 2015 Q4
OPERATING ACTIVITIES
Net Income -$10.64M -$31.05M -$8.439M
YoY Change 32.99% 14.64% 13.4%
Depreciation, Depletion And Amortization $3.302K $16.53K $10.00K
YoY Change -23.56% -4.32%
Cash From Operating Activities -$6.040M -$25.69M -$6.600M
YoY Change -0.17% 5.85% 31.47%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$16.48M $17.82M $4.050M
YoY Change -304.98% -197.22% -10225.0%
Cash From Investing Activities -$16.48M $17.82M $4.050M
YoY Change -304.98% -197.22% -10225.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.440M 76.57M 0.000
YoY Change -54.48% 99.71% -100.0%
NET CHANGE
Cash From Operating Activities -6.040M -25.69M -6.600M
Cash From Investing Activities -16.48M 17.82M 4.050M
Cash From Financing Activities 8.440M 76.57M 0.000
Net Change In Cash -14.08M 68.70M -2.550M
YoY Change -168.58% -1712.68% -49.9%
FREE CASH FLOW
Cash From Operating Activities -$6.040M -$25.69M -$6.600M
Capital Expenditures $0.00
Free Cash Flow -$6.600M
YoY Change 32.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016Q2 dei Entity Public Float
EntityPublicFloat
245659533
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1360569
CY2016Q4 nerv Deferred Related Party Revenue Current
DeferredRelatedPartyRevenueCurrent
2547952
CY2016Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
3841062
CY2015Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8503111
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2016 dei Document Type
DocumentType
10-K
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14284054
CY2015Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
17920632
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
80000
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1196136
CY2015Q4 us-gaap Assets Current
AssetsCurrent
33480822
CY2015Q4 us-gaap Assets
Assets
82576391
CY2016Q4 us-gaap Notes Payable Current
NotesPayableCurrent
4853753
CY2015Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1434756
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
238836940
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
157129947
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-132858234
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101812862
CY2014 us-gaap Operating Expenses
OperatingExpenses
54870431
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.99
CY2014 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
16541834
CY2014 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
10542670
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7423941
CY2014 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
2112000
CY2015 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
166344
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2202235
CY2016 nerv Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
23392098
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
76724
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3571211
CY2016 dei Entity Registrant Name
EntityRegistrantName
Minerva Neurosciences, Inc.
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0001598646
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
34200000
CY2015Q4 us-gaap Goodwill
Goodwill
14869399
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35286433
CY2016 dei Trading Symbol
TradingSymbol
NERV
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-30190696
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7576256
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1468341
CY2016Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
815813
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11961865
CY2015 us-gaap Operating Expenses
OperatingExpenses
26109619
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.47
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31514154
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-56901439
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.16
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23412181
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
20179603
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
51499595
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5319963
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26170
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9685859
CY2015Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2524638
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Liabilities
Liabilities
26960681
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
105982208
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
55319557
CY2015Q4 us-gaap Liabilities
Liabilities
27256834
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
3502
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
132942889
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82576391
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
2472
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42908566
CY2014 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1952309
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
2202235
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
17966611
CY2016 nerv Increase Decrease In Prepaid Expense Other Current Assets
IncreaseDecreaseInPrepaidExpenseOtherCurrentAssets
-372655
CY2014 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2049735
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12724395
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24721143
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35024002
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24721143
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20439994
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9750702
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18533363
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35024002
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
13433760
CY2015Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
13433760
CY2015 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-15853
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-54870431
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-26109619
CY2014 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
18727
CY2016 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1029734
CY2015 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1053070
CY2016 us-gaap Investment Income Interest
InvestmentIncomeInterest
198453
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-27081632
CY2016 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-23395
CY2015 us-gaap Investment Income Interest
InvestmentIncomeInterest
96910
CY2016 us-gaap Operating Expenses
OperatingExpenses
30190696
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-31045372
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
16530
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17276
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
33869
CY2016 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
347771
CY2015 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
377455
CY2016 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
102632
CY2015 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
247262
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
3571211
CY2014 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
10093
CY2015 nerv Increase Decrease In Prepaid Expense Other Current Assets
IncreaseDecreaseInPrepaidExpenseOtherCurrentAssets
400037
CY2014 nerv Increase Decrease In Prepaid Expense Other Current Assets
IncreaseDecreaseInPrepaidExpenseOtherCurrentAssets
713200
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
107772
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
718756
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
368698
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1708825
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
879380
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
112285
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2547952
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1222420
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1222420
CY2015 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-7694
CY2014 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
7694
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-25687674
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-24269419
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-35960846
CY2015 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
23279285
CY2016 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
17818000
CY2015 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
4994683
CY2014 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
1167869
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
44986
CY2014 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
35014
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45609
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
17818000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-18329588
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
1087246
CY2016 nerv Gross Proceeds From Issuance Of Common Stock
GrossProceedsFromIssuanceOfCommonStock
57499995
CY2014 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
31334702
CY2016 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3832004
CY2014 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3159835
CY2016 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
999999
CY2015 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
30999999
CY2014 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
23706118
CY2015 nerv Costs Paid In Connection With Private Placement
CostsPaidInConnectionWithPrivatePlacement
2466984
CY2014 nerv Costs Paid In Connection With Private Placement
CostsPaidInConnectionWithPrivatePlacement
280000
CY2016 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
23392098
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
76724
CY2015 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10000000
CY2014 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1882817
CY2015 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
195656
CY2016 us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
1570583
CY2014 us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
1882817
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
76566229
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
38337359
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
51600985
CY2016 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
68696555
CY2015 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-4261648
CY2014 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
16727385
CY2015Q4 nerv Accrued Research And Development Costs And Other Expenses Current
AccruedResearchAndDevelopmentCostsAndOtherExpensesCurrent
1740871
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
192000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18545702
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1818317
CY2016 us-gaap Interest Paid
InterestPaid
691227
CY2015 us-gaap Interest Paid
InterestPaid
616875
CY2014 us-gaap Interest Paid
InterestPaid
15233
CY2014 us-gaap Stock Issued1
StockIssued1
16541834
CY2014 us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
321417
CY2014 us-gaap Noncash Or Part Noncash Acquisition Other Liabilities Assumed1
NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1
681600
CY2014 nerv Noncash Or Part Noncash Acquisition Deferred Tax Liability Assumed
NoncashOrPartNoncashAcquisitionDeferredTaxLiabilityAssumed
5970560
CY2014 us-gaap Noncash Or Part Noncash Acquisition Other Assets Acquired1
NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1
42926
CY2014 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
28204
CY2014 us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
15200000
CY2014 nerv Noncash Or Part Noncash Acquisition Goodwill Acquired
NoncashOrPartNoncashAcquisitionGoodwillAcquired
7076412
CY2014 nerv Cash Acquired In Business Merger
CashAcquiredInBusinessMerger
1167869
CY2014 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
2112000
CY2016 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE&#160;1&#160;&#8212; NATURE OF OPERATIONS AND LIQUIDITY </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Nature of Operations </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minerva Neurosciences, Inc. (&#8220;Minerva&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (&#8220;CNS&#8221;) diseases. The Company has acquired or in-licensed four development-stage proprietary compounds that it believes have innovative mechanisms of action with potentially positive therapeutic profiles. The Company&#8217;s lead product candidate is MIN-101, a compound for the treatment of patients with schizophrenia. In addition, the Company&#8217;s portfolio includes MIN-202 (also known as JNJ-42847922), a compound the Company is co-developing with Janssen Pharmaceutica NV (&#8220;Janssen&#8221;), for the treatment of patients suffering from primary and comorbid insomnia; MIN-117, a compound the Company is developing for the treatment of patients suffering from major depressive disorder (&#8220;MDD&#8221;); and MIN-301, a compound the Company is developing for the treatment of patients suffering from Parkinson&#8217;s disease.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2013, the Company merged with Sonkei Pharmaceuticals&#160;Inc. (&#8220;Sonkei&#8221;), a clinical-stage biopharmaceutical company and, in February&#160;2014, the Company acquired Mind-NRG, a pre-clinical-stage biopharmaceutical company. The Company refers to these transactions as the Sonkei Merger and Mind-NRG Acquisition, respectively. The Company holds licenses to MIN-101 and MIN-117 from Mitsubishi Tanabe Pharma Corporation (&#8220;MTPC&#8221;) with the rights to develop, sell and import MIN-101 and MIN-117 globally, excluding most of Asia. With the acquisition of Mind-NRG, the Company obtained exclusive rights to develop and commercialize MIN-301. The Company has also entered into a co-development and license agreement with Janssen, for the exclusive rights to develop and commercialize MIN-202 in the European Union, subject to royalty payments to Janssen, and royalty rights for any sales outside the European Union, Switzerland, Liechtenstein, Iceland and Norway (the &#8220;Minerva Territory&#8221;).</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has limited capital resources and has incurred recurring operating losses and negative cash flows from operations since inception. As of December 31, 2016, the Company has an accumulated deficit of approximately <font style="color:#000000;">$132.9 million and net cash used in operating activities was approximately $25.7 million during the year ended December 31, 2016. </font>Management expects to continue to incur operating losses and negative cash flows from operations. The Company has financed its operations to date from proceeds from the sale of common stock, warrants, loans and convertible promissory notes.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its existing cash and cash equivalents will be sufficient to meet its anticipated cash requirements for at least the next 12 months after the date that the financial statements are issued. The process of drug development can be costly and the timing and outcomes of clinical trials is uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and development programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future clinical trials which will be predicated upon adequate funding to complete the trials.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will need to raise additional capital in order to continue to fund operations and fully fund later stage clinical development programs. The Company believes that it will be able to obtain additional working capital through equity financings or other arrangements to fund future operations; however, there can be no assurance that such additional financing, if available, can be obtained on terms acceptable to the Company.&#160;&#160;If the Company is unable to obtain such additional financing, future operations would need to be scaled back or discontinued.</p></div>
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </p></div>
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of credit risk </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. Marketable securities consist primarily of corporate bonds, with fixed interest rates. Exposure to credit risk of marketable securities is reduced by maintaining a diverse portfolio and monitoring their credit ratings. As of December 31, 2016, all marketable securities previously held by the Company have matured or been redeemed.</p></div>
CY2015Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
725017
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
49523
CY2016 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2015 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2014 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2016 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2016 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2015 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2016 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2015 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2016Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
15260809
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
13019045
CY2015Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
17887558
CY2014 us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
-57354314
CY2014 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-4.51
CY2016Q4 nerv Accrued Research And Development Costs And Other Expenses Current
AccruedResearchAndDevelopmentCostsAndOtherExpensesCurrent
574290
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
58750
CY2016Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
8429417
CY2016Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1000000
CY2015Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
31000000
CY2015Q1 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
200000
CY2014Q2 nerv Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber
926604
CY2014Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.08
CY2014Q3 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
6.00
CY2014Q3 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
352000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.13
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
21200000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3571211
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2202235
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17966611
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
20213845
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15037123
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
145115
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
145115
CY2016Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
16413906
CY2015Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
9905448
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4741558
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3660286
CY2016Q4 nerv Deferred Tax Assets Deferred Start Up And License Costs
DeferredTaxAssetsDeferredStartUpAndLicenseCosts
10258431
CY2015Q4 nerv Deferred Tax Assets Deferred Start Up And License Costs
DeferredTaxAssetsDeferredStartUpAndLicenseCosts
11124716
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
51772855
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
39872688
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
51772855
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
39872688
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2016Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
13433760
CY2015Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
13433760
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
13433760
CY2015Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
13433760
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2016 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.0076
CY2015 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.0053
CY2014 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.0427
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0516
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0520
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0462
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.3840
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.3867
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.3435
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
11900000
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
10300000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2014Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-1.53
CY2015Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2014Q3 us-gaap Area Of Land
AreaOfLand
4043
CY2014Q3 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
100000
CY2014Q3 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P2Y
CY2016Q2 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
100000
CY2016Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2018-03-31
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7757000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4965000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8232000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-9237000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-8004000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-5214000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-8423000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-9404000
CY2016Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.29
CY2016Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.18
CY2016Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.24
CY2016Q4 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.27
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5878000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6332000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5705000
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-8194000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-6093000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-6610000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-5939000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-8439000
CY2015Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.31
CY2015Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.27
CY2015Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.24
CY2015Q4 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.34
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2623000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17650000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-27151000
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-7446000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-2938000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-19366000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-27155000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-7442000
CY2014Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.43
CY2014Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-2.55
CY2014Q4 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.40

Files In Submission

Name View Source Status
0001564590-17-004048-index-headers.html Edgar Link pending
0001564590-17-004048-index.html Edgar Link pending
0001564590-17-004048.txt Edgar Link pending
0001564590-17-004048-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2017031021385414834522.jpg Edgar Link pending
g2017031021390562634523.jpg Edgar Link pending
nerv-10k_20161231.htm Edgar Link pending
nerv-20161231.xml Edgar Link completed
nerv-20161231.xsd Edgar Link pending
nerv-20161231_cal.xml Edgar Link unprocessable
nerv-20161231_def.xml Edgar Link unprocessable
nerv-20161231_lab.xml Edgar Link unprocessable
nerv-20161231_pre.xml Edgar Link unprocessable
nerv-ex1036_286.htm Edgar Link pending
nerv-ex211_9.htm Edgar Link pending
nerv-ex231_7.htm Edgar Link pending
nerv-ex311_10.htm Edgar Link pending
nerv-ex312_8.htm Edgar Link pending
nerv-ex321_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending